International Clinical Trial: A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822542) titled 'A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer' on Sept. 11.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Condition: Carcinoma, Non-Small-Cell Lung

Intervention: Drug: HS-10370 Drug: Adebrelimab Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed

Recruitment Status:...